Medical surgery, cell therapy, medical artificial intelligence
EirGenix has core capacity in process development and manufacturing, producing biologics compliant with PIC/S GMP, and has 7 products undergoing development. EirGenix has two main business:
1. Contract Development & Manufacturing Operation
EirGenix produces microbial and mammalian cell based biologics compliant with PIC/S GMP from cell line development to drug substance, and provides process development and quality control (QC) analysis for products.
Cell Line Development & Cell Banking Service:
Contract Development & Manufacturing Service:
Contract Research (CRO) & QC analysis Service:
Antibody Drug Conjugate (ADC) service: Partnering with Formosa Laboratories, Ltd.
2. Product Development & Operations
Trastuzumab Biosimilar (EG12014/EGI014): treats HER2 gene variance cancer. It is undergoing global phase III clinical trial.
Pertuzumab Biosimilar (EG1206A): treats HER2 gene variance cancer.
New Formulation (EG13074): treats HER2 gene variance cancer.
Antibody-Drug Conjugate (TSY0110(EG12043): treats HER2 gene variance cancer.
Bevacizumab Biosimilar (EG12021): inhibits cancer by anti-angiogenesis.
CRM197 Carrier Protein (EG74032): can be used for vaccination.
Biosimilar (EG62054)
1. Handheld Dental X ray machine ( CNT X ray source )
* Battery-powered design
* Compact, portable
* Low radiation dosage, low radiation leakage
* High image quality
* Backscatter shield provied to prevent operator from radiation
exposure
2. Handheld X ray machine for general purpose ( CNT X ray source )
* Automatic SID measurement
* Indication for extremities and chest images application
* Easy operation for Handheld / Mounted / Stand mode
* Easy cleaning in Pandemic
3. X ray sources for brachytherapy (IORT) (CNT X ray source)
* Less malfunction rate than Tungsten X ray source
* Reduction of massive body size of equipment
* Accurate dosage distribution